Annals of Diagnostic Pathology
Volume 11, Issue 4 , Pages 297-311 , August 2007

Histopathology of endometrial hyperplasia and endometrial carcinoma: An update

  • Lars-Christian Horn, MD, PhD

      Affiliations

    • Division of Gynecologic Pathology, Institute of Pathology, Leipzig University, D-04103 Leipzig, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 341 97 150 46; fax: +49 341 97 23 549.
    • ,
  • Alexandra Meinel, MSc

      Affiliations

    • Division of Gynecologic Pathology, Institute of Pathology, Leipzig University, D-04103 Leipzig, Germany
    • ,
  • Romy Handzel, MSc

      Affiliations

    • Department of Obstetrics and Gynecology, Leipzig University, D-04103 Leipzig, Germany
    • ,
  • Jens Einenkel, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Leipzig University, D-04103 Leipzig, Germany

References 

  1. Wilson CM, Tobin S, Young RC. The exploding worldwide cancer burden: the impact of cancer on women. Int J Gynecol Cancer. 2004;14:1–11
  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  3. Gesellschaft der epidemiologischen Krebsregister in Deutschland. Krebs in Deutschland - Häufigkeiten und Trends. Endometrium, Saarbrücken 2006, p. 60-3.
  4. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10–17
  5. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol. 2004;35:649–662
  6. Horn LC, Dietel M, Einenkel J. Hormone replacement therapy (HRT) and endometrial morphology under consideration of the different molecular pathways in endometrial carcinogenesis. Eur J Obstet Gynecol Reprod Biol. 2005;122:4–12
  7. Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer. 2003;98:176–186
  8. Lax SF, Kurman RJ, Pizer ES, et al. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol. 2000;24:1201–1208
  9. Horn L-C, Lax SF, Höckel M, Fischer U, Schmidt D. Präkanzeröse Läsionen des Endometriums: Aspekte der molekularen Pathogenese und Probleme der Nomenklatur. Geburtsh Frauenheilk. 2001;61:8–14
  10. McCluggage WG. My approach to the interpretation of endometrial biopsies and curettings. J Clin Pathol. 2006;59:801–812
  11. Feeley KM, Burton JL, Wells M. A diagnostic approach to endometrial biopsies: selected topics. Curr Diagn Pathol. 2000;6:13–20
  12. Marsden DE, Hacker NF. The classification, diagnosis and management of endometrial hyperplasia. Rev Gynaecol Pract. 2003;3:89–97
  13. Mazur MT. Endometrial hyperplasia/adenocarcinoma. A conventional approach. Ann Diagn Pathol. 2005;9:174–181
  14. Silverberg SG, Kurman RJ, Nogales F, Mutter GL, Kubik-Huch RA, Tavassoli FA. Tumors of the uterine corpus. In:  Tavassoli FA,  Devilee P editor. Pathology and genetics of tumours of the breast and female genital organs. World Health Organization classification of tumours. Lyon, France: IARC Press; 2003;p. 217–232
  15. Acharya S, Hensley ML, Montag AC, Fleming GF. Rare uterine cancers. Lancet Oncol. 2005;6:961–971
  16. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366:491–505
  17. Horn LC, Schnurrbusch U, Bilek K, et al. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer. 2004;14:348–353
  18. Baak JP, Wisse-Brekelmans EC, Fleege JC, et al. Assessment of the risk on endometrial cancer in hyperplasia, by means of morphological and morphometrical features. Pathol Res Pract. 1992;188:856–859
  19. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer. 1985;56:403–412
  20. Beckmann MW, Böing C, Ebert AD, et al. Endometriumkarzinom. In:  Kaufmann M,  Beckmann MW,  Emons G,  Dall P,  Ebert AD,  Hantschmann P, et al. editor. Aktuelle Empfehlungen der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO). Munchen, Wien, New York: Zuckschwerdt; 2006;p. 179–195
  21. Kendall BD, Ronnett BM, Isacson C, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia and well-differentiated carcinoma. Am J Surg Pathol. 1998;22:1012–1019
  22. Bergeron C, Nogales FF, Masseroli M, et al. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol. 1999;23:1102–1108
  23. Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer. 1982;49:2547–2559
  24. Janicek MF, Rosenshein NB. Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia. Gynecol Oncol. 1994;52:373–378
  25. Tavassoli FA, Kraus FT. Endometrial lesions in uteri resected for atypical endometrial hyperplasia. Am J Clin Pathol. 1978;70:770–779
  26. Widra EA, Dunton CJ, McHugh M, et al. Endometrial hyperplasia and the risk of carcinoma. Int J Gynaecol Cancer. 1995;5:233–235
  27. Mecke H, Lüttges J, Lehmann-Willenbroock E, et al. Treatment of precursors of endometrial cancer. Gynecol Obstet Invest. 1994;37:130–134
  28. Mutter GL, Zaino RJ, Baak JP, Bentley RC, Robboy SJ. Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. Int J Gynecol Pathol. 2007;26:103–114
  29. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol. 1997;90:434–440
  30. Kim YB, Holschneider CH, Ghosh K, et al. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer. 1997;79:320–327
  31. Pérez-Medina T, Bajo J, Folgueira G, et al. Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up. Gynecol Oncol. 1999;73:299–304
  32. Kaku T, Tsukamoto N, Hachisuga T, et al. Endometrial carcinoma associated with hyperplasia. Gynecol Oncol. 1996;60:22–25
  33. Ambros RA, Sherman ME, Zahn CM, et al. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol. 1995;26:1260–1267
  34. Mutter GL. Histopathology of genetically defined endometrial precancers. Int J Gynecol Pathol. 2000;19:301–309
  35. McCluggage WG, Sumathi VP, McManus D. Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endometrial polyps: report of 5 cases, including 2 associated with tamoxifen therapy. Hum Pathol. 2003;34:939–943
  36. Wheeler DT, Bell KA, Kurman RJ, et al. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol. 2000;24:797–806
  37. Zheng W, Liang SX, Yi X, et al. Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma. Int J Gynecol Pathol. 2007;26:38–52
  38. Norris HJ, Tavassoli FA, Kurman RJ. Endometrial hyperplasia and carcinoma. Diagnostic considerations. Am J Surg Pathol. 1983;7:839–847
  39. Longacre TA, Chung MH, Jensen DN, et al. Proposed criteria for the diagnosis of well-differentiated endometrial carcinoma. A diagnostic test for myoinvasion. Am J Surg Pathol. 1995;19:371–406
  40. Ioffe OB. Recent developments and selected diagnostic problems in carcinomas of the endometrium. Am J Clin Pathol. 2005;124(Suppl):S42–S51
  41. Mittal KR, Barwick KW. Diffusely infiltrating adenocarcinoma of the endometrium. A subtype with poor prognosis. Am J Surg Pathol. 1988;12:754–758
  42. Mai KT, Perkins DG, Yazdi HM, et al. Endometrioid carcinoma of the endometrium with an invasive component of minimal deviation carcinoma. Hum Pathol. 2002;33:856–858
  43. Landry D, Mai KT, Senterman MK, et al. Endometrioid adenocarcinoma of the uterus with a minimal deviation invasive pattern. Histopathology. 2003;42:77–82
  44. Nanbu K, Konishi I, Yamamoto S, et al. Minimal deviation adenocarcinoma of endometrioid type may arise in the isthmus: clinicopathological and immunohistochemical study of two cases. Gynecol Oncol. 1995;58:136–141
  45. Longacre TA, Hendrickson MR. Diffusely infiltrative endometrial adenocarcinoma: an adenoma malignum pattern of myoinvasion. Am J Surg Pathol. 1999;23:69–78
  46. Hendrickson M, Ross J, Eifel P, et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6:93–108
  47. Trope C, Kristensen GB, Abeler VM. Clear-cell and papillary serous cancer: treatment options. Best Pract Res Clin Obstet Gynaecol. 2001;15:433–446
  48. Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91:463–469
  49. Carcangiu ML, Tan LK, Chambers JT. Stage IA uterine serous carcinoma: a study of 13 cases. Am J Surg Pathol. 1997;21:1507–1514
  50. Munkarah AR. The controversies surrounding the management of uterine serous carcinoma. Cancer. 2004;101:2152–2154
  51. Umpierre SA, Burke TW, Tornos C, et al. Immunocytochemical analysis of uterine papillary serous carcinomas for estrogen and progesterone receptors. Int J Gynecol Pathol. 1994;13:127–130
  52. Al-Hussaini M, Stockmann A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44:109–115
  53. Boruta DM, Gehrig PA, Groben PA, et al. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?. Cancer. 2004;101:2214–2221
  54. Abeler VM, Kjorstad KE. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. Gynecol Oncol. 1991;40:207–217
  55. Carcangiu ML, Chambers JT. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int J Gynecol Pathol. 1995;14:30–38
  56. Cirisano FD, Robboy SJ, Dodge RK, et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol. 1999;74:385–394
  57. Scully RE, Barlow JF. “Mesonephroma” of ovary. Tumor of mullerian nature related to endometrioid carcinoma. Cancer. 1967;20:1405–1417
  58. Lax SF, Pizer ES, Ronnett BM, et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol. 1998;29:551–558
  59. Goodman A, Zukerberg LR, Rice LW, et al. Squamous cell carcinoma of the endometrium: a report of eight cases and a review of the literature. Gynecol Oncol. 1996;61:54–60
  60. Rodolakis A, Papaspyrou I, Sotiropoulou M, et al. Primary squamous cell carcinoma of the endometrium. A report of 3 cases. Eur J Gynaecol Oncol. 2001;22:143–146
  61. Zidi YS, Bouraoui S, Atallah K, et al. Primary in situ squamous cell carcinoma of the endometrium, with extensive squamous metaplasia and dysplasia. Gynecol Oncol. 2003;88:444–446
  62. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. Int J Gynaecol Obstet. 2003;83(Suppl 1):79–118
  63. Lininger RA, Ashfaq R, Albores-Saavedra J, et al. Transitional cell carcinoma of the endometrium and endometrial carcinoma with transitional cell differentiation. Cancer. 1997;79:1933–1943
  64. Ahluwalia M, Light AM, Surampudi K, et al. Transitional cell carcinoma of the endometrium: a case report and review of the literature. Int J Gynecol Pathol. 2006;25:378–382
  65. Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol. 2004;11:117–142
  66. Eichhorn JH, Young RH, Clement PB. Sertoliform endometrial adenocarcinoma: a study of four cases. Int J Gynecol Pathol. 1996;15:119–126
  67. Ordi J, Schammel DP, Rasekh L, et al. Sertoliform endometrioid carcinomas of the ovary: a clinicopathologic and immunohistochemical study of 13 cases. Mod Pathol. 1999;12:933–940
  68. Huntsman DG, Clement PB, Gilks CB, et al. Small-cell carcinoma of the endometrium. A clinicopathological study of sixteen cases. Am J Surg Pathol. 1994;18:364–375
  69. Clement PB, Young RH. Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol. 2002;9:145–184
  70. Stachs A, Makovitzky J, Briese V. Small cell carcinoma of the endometrium: light microscopic and immunohistochemical study of a case. Anticancer Res. 2005;25:1823–1825
  71. Eichhorn JH, Young RH. Neuroendocrine tumors of the genital tract. Am J Clin Pathol. 2001;115(Suppl):S94–S112
  72. Hoffman K, Nekhlyudov L, Deligdisch L. Endometrial carcinoma in elderly women. Gynecol Oncol. 1995;58:198–201
  73. Craighead PS, Sait K, Stuart GC, et al. Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994. Gynecol Oncol. 2000;77:248–253
  74. Horn LC, Hanel C, Bartholdt E, et al. Serous carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature indicate the existence of 2 prognostically relevant tumor types. Int J Gynecol Pathol. 2006;25:247–251
  75. Pekin T, Yildizhan B, Eren F, et al. Adenocarcinoma, adenoacanthoma, and mixed adenosquamous carcinoma of the endometrium. Eur J Gynaecol Oncol. 2001;22:151–153
  76. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991;40:55–65
  77. Varras M, Polyzos D, Akrivis Ch. Effects of tamoxifen on the human female genital tract: review of the literature. Eur J Gynaecol Oncol. 2003;24:258–268
  78. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 2004;94:256–266
  79. Seoud M, Shamseddine A, Khalil A, et al. Tamoxifen and endometrial pathologies: a prospective study. Gynecol Oncol. 1999;75:15–19
  80. Deligdisch L, Kalir T, Cohen CJ, et al. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol. 2000;78:181–186
  81. Kommoss F, Karck U, Prompeler H, et al. Steroid receptor expression in endometria from women treated with tamoxifen. Gynecol Oncol. 1998;70:188–191
  82. Acharya S, Hensley ML, Montag AC, et al. Rare uterine cancers. Lancet Oncol. 2005;6:961–971
  83. Wilder JL, Shajahan S, Khattar NH, et al. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study. Gynecol Oncol. 2004;92:553–558
  84. Petru E, Kurschel S, Walsberger K. Screening asmyptomatischer Frauen auf Endometriumkarzinom mit besonderer Berücksichtigung des Screenings unter Tamoxifen-Behandlung. Geburtsh Frauenheilk. 2000;60:297–301
  85. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354:261–269
  86. Vasen HF, Stormorken A, Menko FH, et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol. 2001;19:4074–4080
  87. Renkonen-Sinisalo L, Butzow R, Leminen A, et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer. 2007;120:821–824
  88. Chung L, Broaddus R, Crozier M, et al. Unexpected endometrial cancer at prophylactic hysterectomy in a woman with hereditary nonpolyposis colon cancer. Obstet Gynecol. 2003;102:1152–1155
  89. Coffey D, Kaplan AL, Ramzy I. Intraoperative consultation in gynecologic pathology. Arch Pathol Lab Med. 2005;129:1544–1557
  90. Fishman A, Altaras M, Bernheim J, et al. The value of transvaginal sonography in the preoperative assessment of myometrial invasion in high and low grade endometrial cancer and in comparison to frozen section in grade 1 disease. Eur J Gynaecol Oncol. 2000;21:128–130
  91. Atad J, Weill S, Ben-David Y, et al. Intraoperative frozen section examination of myometrial invasion depth in patients with endometrial carcinoma. Int J Gynecol Cancer. 1994;4:352–355
  92. Silverberg SG. Protocol for the examination of specimens from patients with carcinomas of the endometrium: a basis for checklists. Cancer Committee, College of American Pathologists. Arch Pathol Lab Med. 1999;123:28–32

PII: S1092-9134(07)00085-8

doi: 10.1016/j.anndiagpath.2007.05.002

Annals of Diagnostic Pathology
Volume 11, Issue 4 , Pages 297-311 , August 2007

Article Tools

* Image Usage & Resolution